Skip to content

TruSpine Technolgs. - Further re: FDA Update

Announcement provided by

TruSpine Technologies Plc · TSP

30/10/2023 07:00

TruSpine Technolgs. - Further re: FDA Update
RNS Number : 6249R
TruSpine Technologies PLC
30 October 2023




30 October 2023


TruSpine Technologies plc

("TruSpine" or the "Company")


Further re: FDA Update

TruSpine Technologies plc, (AQSE: TSP) the medical device company focused on the development of its pioneering "screwless," spinal (vertebral) stabilisation systems announces that, further to the announcement on 12 October 2023, the Company has received communication from the U.S. Food and Drug Administration ("FDA") that its FDA 510(k) application has been progressed to the substantive review stage.

CEO Laurence Strauss commented: "I am delighted that after the prompt response of the Company in providing clarification and documentation to the US FDA in support of our 510(k) application for Cervi-LOK,  the FDA have moved the application on to the substantive review stage. I hope to be able to provide news of further developments in the near future."

This announcement contains inside information for the purposes of the UK Market Abuse Regulation, and the Directors of the Company are responsible for the release of this announcement.


TruSpine Technologies Plc

Tel: +44 (0)20 7118 0852

Laurence Strauss, Chief Executive Officer

Cairn Financial Advisers LLP (AQSE Corporate Adviser)

Tel: +44 (0)20 7213 0880

Liam Murray / Ludovico Lazzaretti

Peterhouse Capital Limited (Broker & Financial Adviser)

Tel: +44 (0)20 7469 0930

Lucy Williams / Duncan Vasey


Novus Communications (PR and IR)

Tel: +44 (0)1273 704473

Alan Green / Jacqueline Briscoe


Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

View more ...

TSP announcementsAll announcements


  • About
  • News
  • Investor Relations
  • Contact
  • Careers

© Aquis Exchange 2024. All rights reserved.

Terms & ConditionsPrivacy PolicyModern Slavery & Human Trafficking Policy
System statusnormal